Showing results (161-170 of 343) with videos related to
Sort By:
Pageof 35
Current Drug Targets|August 12, 2009
First-line treatment of multiple myeloma in elderly patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspectivePellegrino Musto, Fiorella D'Auria, Giuseppe Pietrantuono, et al.Journal of Clinical Medicine|October 19, 2019
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma PatientsMarina Silvia Parisi, Salvatore Leotta, Alessandra Romano, et al.Journal of Clinical Medicine|July 29, 2025
Length of Washout Period After Remission Does Not Influence Relapse Risk in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents Combined with VenetoclaxFanny Erika Palumbo, Andrea Duminuco, Laura Longo, et al.Oncotarget|March 12, 2016
Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)Cesarina Giallongo, Daniele Tibullo, Nunziatina L Parrinello, et al.Critical Reviews in Oncology/Hematology|January 11, 2014
Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013Massimo Breccia, Giuliana Alimena, Michele Baccarani, et al.Blood|June 7, 2003
Clinico-biologic features and treatment outcome of adult pro-B-ALL patients enrolled in the GIMEMA 0496 study: absence of the ALL1/AF4 and of the BCR/ABL fusion genes correlates with a significantly better clinical outcomeGiuseppe Cimino, Loredana Elia, Marco Mancini, et al.Cancers|February 2, 2021
CD123 Is Consistently Expressed on NPM1-Mutated AML CellsVincenzo Maria Perriello, Ilaria Gionfriddo, Roberta Rossi, et al.Cell Death & Disease|September 22, 2019
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myelomaCesarina Giallongo, Daniele Tibullo, Giuseppina Camiolo, et al.European Journal of Medicinal Chemistry|September 28, 2018
Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell linesValeria Sorrenti, Valeria Pittalà, Giuseppe Romeo, et al.Journal of Clinical Medicine|August 14, 2025
Does the Timing of Response Impact the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents? A Proof of Concept from a Monocentric Observational StudyErmelinda Longo, Fanny Erika Palumbo, Andrea Duminuco, et al.Pageof 35